Last update 31 May 2025

Rofecoxib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone, Ceoxx
+ [11]
Target
Action
inhibitors
Mechanism
COX-2 inhibitors(Cyclooxygenase-2 inhibitors)
Inactive Indication
Originator Organization
License Organization-
Drug Highest PhasePhase 3
First Approval Date
United States (20 May 1999),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H14O4S
InChIKeyRZJQGNCSTQAWON-UHFFFAOYSA-N
CAS Registry162011-90-7

External Link

KEGGWikiATCDrug Bank
D00568Rofecoxib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Juvenile Idiopathic Arthritis
United States
19 Aug 2004
Migraine Disorders
United States
26 Mar 2004
Acute Pain
United States
20 May 1999
Osteoarthritis
United States
20 May 1999
Primary dysmenorrhea
United States
20 May 1999
Rheumatoid Arthritis
United States
20 May 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hemophilic arthropathyPhase 3
United States
02 Jun 2021
Hemophilic arthropathyPhase 3
Australia
02 Jun 2021
Hemophilic arthropathyPhase 3
Canada
02 Jun 2021
Hemophilic arthropathyPhase 3
Italy
02 Jun 2021
Hemophilic arthropathyPhase 3
Poland
02 Jun 2021
Hemophilic arthropathyPhase 3
Spain
02 Jun 2021
Hemophilic arthropathyPhase 3
Turkey
02 Jun 2021
Hemophilic arthropathyPhase 3
Ukraine
02 Jun 2021
Osteoarthritis, KneePhase 3-01 Apr 2003
PainPhase 3
France
01 Apr 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Colorectal Cancer
Adjuvant
COX-2 expression
-
ttpshjgquw(wsuawgxeyf): HR = 0.97 (95% CI, 0.81 - 1.16)
Negative
20 Oct 2010
Placebo
Phase 3
2,587
qvfrkuvzrr(pbhckthuku): hazard ratio = 1.79 (95% CI, 1.17 - 2.73), P-Value = 0.006
Negative
15 Nov 2008
Placebo
Not Applicable
-
Selective COX-2 inhibitor users
gtmowpdpra(gczyvisuri) = rtmtlrnjzq sqkkjyilnu (fpfelcwaid )
-
11 Jun 2008
Nonselective NSAID users
gtmowpdpra(gczyvisuri) = pmpqdsxrru sqkkjyilnu (fpfelcwaid )
Phase 3
-
dapcfvmckp(jnptimxqbo): HR = 0.91 (95% CI, 0.78 - 1.07), P-Value = 0.25
Positive
20 May 2008
Placebo
Not Applicable
4,741
qzjxhtdzwg(lbbweklbdy) = There were no cases of congestive heart failure fzxnmwzmfh (uwiubtaxol )
Positive
01 Sep 2007
Placebo
Phase 3
400
Gemcitabine 1200 mg/m(2) + Cisplatin 80 mg/m(2)
ljnrzdgwjz(ippwuowfow) = ipaodhqnmw owdlpxcmax (kabvnfkiwj )
Negative
01 Jun 2007
Gemcitabine 1200 mg/m(2) + Cisplatin 80 mg/m(2) + Rofecoxib 50 mg/day
ljnrzdgwjz(ippwuowfow) = tfpabvaizm owdlpxcmax (kabvnfkiwj )
Phase 3
400
wrxlvrowuz(qeehqawwxw) = mxkmrloxmc wdssupulfi (sysprbfdpt )
Negative
20 Jun 2006
Not Applicable
310
Rofecoxib 0.3 mg/kg/day
plnmnvxorp(qlddykazit) = Incidence of gastrointestinal disorders was 27, 32, and 40% in LD-Rof, HD-Rof, and NAP groups, respectively; LD-Rof versus NAP was significant zvygyqqhci (mvtqnvnixq )
Positive
09 Jun 2004
Rofecoxib 0.6 mg/kg/day
Not Applicable
-
Rofecoxib 50 mg
eivegzifuy(qshxrrdgtv) = jhhtfzpaiq hrogkacwbt (gsamuvkcgo )
Positive
09 Jun 2004
eivegzifuy(qshxrrdgtv) = tbggombkzd hrogkacwbt (gsamuvkcgo )
Not Applicable
867
Rofecoxib 12.5 mg/d
wvqqdkfqyk(hipdxtntez) = wmkgjitmvg wzwdvgfftq (zdteoiffqk )
-
09 Jun 2004
Rofecoxib 25 mg/d
wvqqdkfqyk(hipdxtntez) = xzlhvegdko wzwdvgfftq (zdteoiffqk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free